BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

754 related articles for article (PubMed ID: 31365094)

  • 21. Reversal of carbapenemase-producing Klebsiella pneumoniae epidemiology from blaKPC- to blaVIM-harbouring isolates in a Greek ICU after introduction of ceftazidime/avibactam.
    Papadimitriou-Olivgeris M; Bartzavali C; Lambropoulou A; Solomou A; Tsiata E; Anastassiou ED; Fligou F; Marangos M; Spiliopoulou I; Christofidou M
    J Antimicrob Chemother; 2019 Jul; 74(7):2051-2054. PubMed ID: 31002313
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular mechanisms responsible KPC-135-mediated resistance to ceftazidime-avibactam in ST11-K47 hypervirulent
    Shi Q; Shen S; Tang C; Ding L; Guo Y; Yang Y; Wu S; Han R; Yin D; Hu F
    Emerg Microbes Infect; 2024 Dec; 13(1):2361007. PubMed ID: 38801099
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular Mechanisms Driving the
    Li X; Ke H; Wu W; Tu Y; Zhou H; Yu Y
    mSphere; 2021 Dec; 6(6):e0085921. PubMed ID: 34935448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activity of ceftazidime-avibactam alone and in combination with polymyxin B against carbapenem-resistant Klebsiella pneumoniae in a tandem in vitro time-kill/in vivo Galleria mellonella survival model analysis.
    Borjan J; Meyer KA; Shields RK; Wenzler E
    Int J Antimicrob Agents; 2020 Jan; 55(1):105852. PubMed ID: 31770627
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emergence of ceftazidime-avibactam resistance in bla
    Zhou J; Yan G; Tang C; Liu J; Fu P; Ding L; Yang W; Guo Y; Wang C; Lu G; Hu F
    Int J Antimicrob Agents; 2024 Jun; 63(6):107163. PubMed ID: 38570018
    [TBL] [Abstract][Full Text] [Related]  

  • 26. KPC-2 allelic variants in
    Sanz MB; Pasteran F; de Mendieta JM; Brunetti F; Albornoz E; Rapoport M; Lucero C; Errecalde L; Nuñez MR; Monge R; Pennini M; Power P; Corso A; Gomez SA
    Microbiol Spectr; 2024 Mar; 12(3):e0411123. PubMed ID: 38319084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro mimicry of in vivo KPC mutations by ceftazidime-avibactam: phenotypes, mechanisms, genetic structure and kinetics of enzymatic hydrolysis.
    Shen S; Tang C; Yang W; Ding L; Han R; Shi Q; Guo Y; Yin D; Hu F
    Emerg Microbes Infect; 2024 Dec; 13(1):2356146. PubMed ID: 38743401
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae.
    Haidar G; Clancy CJ; Chen L; Samanta P; Shields RK; Kreiswirth BN; Nguyen MH
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activity of Ceftazidime-Avibactam Against Clinical Isolates of Klebsiella pneumoniae, Including KPC-Carrying Isolates, Endemic to New York City.
    Manning N; Balabanian G; Rose M; Landman D; Quale J
    Microb Drug Resist; 2018; 24(1):35-39. PubMed ID: 28590820
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Deciphering variable resistance to novel carbapenem-based β-lactamase inhibitor combinations in a multi-clonal outbreak caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam.
    Di Pilato V; Principe L; Andriani L; Aiezza N; Coppi M; Ricci S; Giani T; Luzzaro F; Rossolini GM
    Clin Microbiol Infect; 2023 Apr; 29(4):537.e1-537.e8. PubMed ID: 36414199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo selection of KPC-94 and KPC-95 in Klebsiella pneumoniae isolates from patients treated with ceftazidime/avibactam.
    Guzmán-Puche J; Pérez-Nadales E; Pérez-Vázquez M; Causse M; Gracia-Ahufinger I; Mendez-Natera A; Allalou-Ruiz Y; Elías C; Oteo-Iglesias J; Torre-Cisneros J; Martínez-Martínez L
    Int J Antimicrob Agents; 2022 Feb; 59(2):106524. PubMed ID: 35038557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in KPC-producing Klebsiella pneumoniae infections: A case series.
    van Asten SAV; Boattini M; Kraakman MEM; Bianco G; Iannaccone M; Costa C; Cavallo R; Bernards AT
    J Infect Chemother; 2021 May; 27(5):778-780. PubMed ID: 33558042
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resistance to Ceftazidime-Avibactam Is Due to Transposition of KPC in a Porin-Deficient Strain of Klebsiella pneumoniae with Increased Efflux Activity.
    Nelson K; Hemarajata P; Sun D; Rubio-Aparicio D; Tsivkovski R; Yang S; Sebra R; Kasarskis A; Nguyen H; Hanson BM; Leopold S; Weinstock G; Lomovskaya O; Humphries RM
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739787
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutations in
    Haidar G; Clancy CJ; Shields RK; Hao B; Cheng S; Nguyen MH
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223379
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Yu F; Lv J; Niu S; Du H; Tang YW; Bonomo RA; Kreiswirth BN; Chen L
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29891605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analyses of a Ceftazidime-Avibactam-Resistant
    Castanheira M; Arends SJR; Davis AP; Woosley LN; Bhalodi AA; MacVane SH
    mSphere; 2018 Sep; 3(5):. PubMed ID: 30258039
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Effect of β-Lactam Antibiotics on the Evolution of Ceftazidime/Avibactam and Cefiderocol Resistance in KPC-Producing Klebsiella pneumoniae.
    Zhang P; Hu H; Shi Q; Sun L; Wu X; Hua X; McNally A; Jiang Y; Yu Y; Du X
    Antimicrob Agents Chemother; 2023 Mar; 67(3):e0127922. PubMed ID: 36794957
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activity of Ceftazidime-Avibactam Alone and in Combination with Ertapenem, Fosfomycin, and Tigecycline Against Carbapenemase-Producing
    Ojdana D; Gutowska A; Sacha P; Majewski P; Wieczorek P; Tryniszewska E
    Microb Drug Resist; 2019 Nov; 25(9):1357-1364. PubMed ID: 31295055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ceftazidime-Avibactam Resistance Associated with Increased
    Coppi M; Di Pilato V; Monaco F; Giani T; Conaldi PG; Rossolini GM
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cross-resistance to cefiderocol and ceftazidime-avibactam in KPC β-lactamase mutants and the inoculum effect.
    Hobson CA; Cointe A; Jacquier H; Choudhury A; Magnan M; Courroux C; Tenaillon O; Bonacorsi S; Birgy A
    Clin Microbiol Infect; 2021 Aug; 27(8):1172.e7-1172.e10. PubMed ID: 33915286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.